ANTHEM · Healthcare · Biotechnology
Composite scorecard: 59/100 — Quality 95 · Valuation 22 · Momentum 39
| Share price | ₹791.55 |
| Market cap | ₹42,393 Cr |
| P/E ratio | 71.9 |
| P/B ratio | 13.9 |
| ROE | 23.0% |
| ROCE | 26.8% |
| Dividend yield | 0.27% |
| Book value | ₹54.16 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,124 Cr | ₹592 Cr | 39.0% |
| 2025 | ₹1,845 Cr | ₹451 Cr | 36.0% |
| 2024 | ₹1,419 Cr | ₹367 Cr | 36.0% |
| 2023 | ₹1,057 Cr | ₹385 Cr | 41.0% |
| 2022 | ₹1,231 Cr | ₹406 Cr | 46.0% |
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-dr